Effect of Assessing Risk for Osteoporosis on Physician and Patient Behaviors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01572766|
Recruitment Status : Completed
First Posted : April 6, 2012
Last Update Posted : April 6, 2012
|Condition or disease||Intervention/treatment|
|Osteoporosis Osteopenia||Other: FRAX Assessment Tool|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Impact of the FRAX Assessment on Physician and Patient Treatment Behavior|
|Study Start Date :||February 2010|
|Primary Completion Date :||November 2010|
|Study Completion Date :||February 2011|
Active Comparator: FRAX Assessment
FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
Other: FRAX Assessment Tool
FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
Other Name: WHO FRAX Risk Assessment Tool
No Intervention: Control group
Control group receives heel ultrasound and pharmacist counseling
- Behavior Change [ Time Frame: After 3 months or greater from screening. ]Patient Health behavior changes included beginning exercise, initiating calcium and vitamin D supplements, talking with physician about osteoporosis prevention, screening by DXA scan, changing dietary intake of calcium; physician behavior changes included ordering a DXA scan, ordering vitamin D blood levels, initiating drug treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01572766
|United States, Pennsylvania|
|Duquesne University Center for Pharmacy Care|
|Pittsburgh, Pennsylvania, United States, 15282|
|Principal Investigator:||Hildegarde J Berdine, PharmD||Duquesne University|